🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension

RecruitingPhase 2Ages 18 Years - 65 YearsAllVanda Pharmaceuticals
NCT07090161 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * SiSBP \>/= 130 mmHg despite \>8 weeks treatment w/ 1 or more antihypertensive therapies Exclusion Criteria: * Confirmed Grade 3/severe hypertension (SiSBP \>/= 180 mmHg, SiDBP \>/= 120 mmHg), unstable cardiac disease, renal insufficiency
💊

What it tests

  • iloperidone
  • Placebo
📍

Where

28 sites
Vanda Investigative Site
Phoenix, United States
Vanda Investigative Site
Tempe, United States
Vanda Investigative Site
Tucson, United States
Vanda Investigative Site
Chula Vista, United States
Vanda Investigative Site
Dublin, United States
Vanda Investigative Site
Valencia, United States
Vanda Investigative Site
Walnut Creek, United States
Vanda Investigative Site
Doral, United States

…and 20 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy